Physician profile
David E Utley
NPI 1902036296
$2,812.60
in general payments reported to CMS, 2019-2025
27 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2023: $611 · 2024: $928 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.12 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Otsuka America Pharmaceutical, INC. | $498.02 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $184.05 | 2019-2025 | |
| Novo Nordisk INC | $184.02 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $174.44 | 2019-2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $154.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $129.88 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $110.95 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.33 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.21 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $93.64 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $85.25 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $71.82 | 2023-2024 | Azstarys |
| Sumitomo Pharma America, INC. | $66.49 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $51.43 | 2023-2024 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $43.18 | 2025 | Omnipod |
| Edwards Lifesciences Corporation | $39.99 | 2019 | |
| Lundbeck LLC | $30.53 | 2024 | Rexulti |
| Dexcom, INC. | $21.81 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.56 | 2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $15.54 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.38 | 2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $14.19 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.96 | 2023 | Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Utley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.